Pruritus News and Research

RSS
EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Acupuncture can be more effective in treatment of dermatologic conditions

Acupuncture can be more effective in treatment of dermatologic conditions

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014